For patients with T2D, efsitora’s simple, once-weekly fixed-dose regimen may simplify the initiation and management of insulin therapy for both parties, which aligns with observations for another once-weekly insulin, insulin icodec (30–34). The gene discussed is INS; the disease is type 2 diabetes mellitus.